Witryna1 mar 2024 · PARPis re-exposure was prospectively investigated for the first time in the phase IIIb OReO/ENGOT Ov-38 trial (NCT03106987). ... et al. Response to chemotherapy and clinical outcome of patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a multicenter retrospective italian study. … Witryna987TiP OReO/ENGOT Ov-38: A phase IIIb trial of olaparib maintenance retreatment in patients with epithelial ovarian cancer E. Pujade-Lauraine1, ... 988TiP ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian …
PARP Inhibitors as Initial Treatment for Ovarian Cancer
Witryna14 kwi 2024 · Survival outcomes for patients with advanced ovarian cancer remain poor despite advances in chemotherapy and surgery. Platinum-based systemic chemotherapy can result in a response rate of up to 80%, but most patients will have recurrence and die from the disease. Recently, the DNA-repair-directed precision oncology strategy has … WitrynaBackground: Despite impressive progression-free survival (PFS) results from PARP inhibitors (PARPi) in ovarian cancer, concerns about their effect on post-progression treatment outcomes have recently arisen, particularly when administered in the relapsed setting. Overlapping mechanisms of resistance between PARPi and platinum have … halo 5 guardian couch coop
Annals of Oncology abstracts
Witryna21 wrz 2024 · OReO/ENGOT Ov-38 is a phase 3, randomized, double-blind trial that enrolled 220 patients with nonmucinous platinum-sensitive relapsed ovarian cancer who received 1 prior line of PARP inhibitor maintenance and were in response to their most recent platinum-based chemotherapy. Witryna23 wrz 2024 · CancerNetwork® sat down with David O’Malley, MD, at the 2024 European Society for Medical Oncology to talk about the OReO trial and how these … Witryna17 wrz 2024 · Whether patients with prior PARP inhibitor maintenance therapy will benefit from PARP-inhibitor rechallenge response to platinum chemotherapy remained unclear. Investigators in the multicenter randomized OReO/ENGOT Ov-38 trial sought to answer the question. The study included a total of 220 patients with relapsed, … burke community church jobs